FDA's on­col­o­gy ad­comm votes against Am­gen's con­fir­ma­to­ry da­ta for Lumakras in cer­tain types of NSCLC

The FDA and its on­col­o­gy ad­vi­so­ry com­mit­tee raised lots of ques­tions on whether Am­gen’s con­fir­ma­to­ry tri­al is enough to con­vert an ac­cel­er­at­ed ap­proval to a full ap­proval for Lumakras (so­tora­sib) to treat those with KRAS G12C mu­tat­ed lo­cal­ly ad­vanced or metasta­t­ic non-small cell lung can­cer (NSCLC).

And the ad­comm vot­ed 10 to 2 against whether the pri­ma­ry end­point, pro­gres­sion-free sur­vival (PFS) per blind­ed in­de­pen­dent cen­tral re­view (BI­CR), can be re­li­ably in­ter­pret­ed in the con­fir­ma­to­ry tri­al, known as Code­BreaK 200.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER